Previous close | 0.5700 |
Open | 0.9800 |
Bid | 1.0000 |
Ask | 1.1300 |
Strike | 2.50 |
Expiry date | 2024-05-24 |
Day's range | 0.8000 - 0.9700 |
Contract range | N/A |
Volume | |
Open interest | 167 |
Peloton isn't profitable as a subscription business, but it looks different as a media company.
Amgen is the latest biotech to benefit from obesity drug optimism, Sony and Apollo offer Paramount Global $26 billion cash in takeover move, and other news to start your day.
Amidst leadership transitions and market adjustments, Peloton reports a significant quarter with strategic restructuring and a focus on sustainable growth.